Future of ADCs: Accelerating Progress in Ovarian and Endometrial Cancer
Activity Overview
The GOG Foundation, Inc. and GOG Partners welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to join us for the Future of ADCs: Accelerating Progress in Ovarian and Endometrial Cancer, an Educational Symposium being presented at the FSGO 2026 Annual Meeting in Long Boat Key, Florida a on Sunday, June 14, 2026 from 8:00 am – 8:50 am ET.
This educational activity is supported by an independent medical education grant from GSK.
Course Description
The era of antibody–drug conjugates (ADCs) in gynecologic oncology have shifted from promise to intense competition. In ovarian and endometrial cancers, platforms targeting FRα, HER2/HER3, TROP2, B7-H4, CDH6, and NaPi2b are advancing rapidly. Mirvetuximab soravtansine has improved outcomes for FRα-positive ovarian cancer, while trastuzumab deruxtecan has extended HER2-directed therapy to certain endometrial tumors. Next-generation ADCs are improving antigen selection, internalization, payload potency, and linker stability to address antigen heterogeneity, resistance, and class-specific toxicities highlighted in recent studies. This symposium will provide a clear, evidence-based overview of the ADC landscape. Faculty will differentiate competing designs, evaluate key and emerging trial data, and offer practical guidance on sequencing, toxicity management, and biomarker-driven patient selection. The program will also highlight active trials and company strategies shaping future standards of care, ensuring participants are prepared to incorporate ADC advances into practice with confidence and clarity.
Target Audience
Gynecologic and medical oncologists, oncology researchers, clinical trial investigators, advanced practice providers, and healthcare professionals involved in the care of patients with ovarian cancer.
Learning Objectives
By the end of this session, participants will be able to:
- Differentiate the design components of ADCs (targets, payloads, and linkers) and describe how antigen density, internalization, and bystander effects impact efficacy, safety, and sequencing in ovarian and endometrial cancers.
- Assess key and emerging clinical data to identify current leaders and anticipate agents likely to set new standards of care.
- Utilize biomarker-driven methods (FRα, HER2/HER3, TROP2, B7-H4, CDH6, NaPi2b) for selecting patients and planning therapy.
- Implement strategies for sequencing ADCs with existing regimens and managing key toxicities such as ocular events and interstitial lung disease.
- Identify suitable clinical trial opportunities and advise eligible patients on participation.
Faculty
Scott Jordan, MD (moderator)
Broward Health
Megan Indermaur, MD
Women’s Care Florida
Marty Martino, MD
Ascension Florida
Agenda
Future of ADCs: Accelerating Progress in Ovarian and Endometrial Cancer, an Educational Symposium at the 2026 FSGO Annual Meeting.
This session is not included in the main event CME/CPD credit.
Scott Jordan, MD, Broward Health
Megan Indermaur, MD, Women’s Care Florida
Marty Martino, MD, Ascension Florida
All Faculty
All Faculty
All Faculty
Accreditation Statement
The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.
The GOG Foundation, Inc. designates this internet live activity for a maximum of 0.75AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Declaration
In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations.The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.
Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.
All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.
NEW TERM *An “ineligible company” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.